Lee SSF, et al. - Researchers retrospectively determined the effectiveness of levofloxacin in preventing hospital readmission due to febrile neutropenia in acute myeloid leukemia (AML) patients who were or were not prescribed levofloxacin post-consolidation chemotherapy. Also, the safety of this therapy was investigated by evaluating the rate of Clostridium difficile-associated diarrhea (CDAD) within 30 days from discharge of receiving consolidation chemotherapy and rate of fluoroquinolone resistance in positive bacterial cultures. An attenuation in febrile neutropenia was noted in association with prescribing oral levofloxacin post-consolidation chemotherapy in AML patients. Compared to those not prescribed levofloxacin, CDAD did not occur in any patient prescribed levofloxacin after the first cycle.